No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy

byKathleen Lau

June 4, 2021

in StudyGraphics

Image-guided salvage radiotherapy improves outcomes in patients with prostate cancer

RelatedReports

Hybrid minimally invasive esophagectomy associated with lower complication rates compared to open esophagectomy

Chronic Disease

Camrelizumab may be safe and effective in the management of locally advanced esophageal squamous cell carcinoma

March 19, 2026

Variation noted across pre- and post-marketing studies for FDA approved devices

Hematology

FDA grants priority review for iberdomide-based myeloma regimen

March 6, 2026

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

All Specialties

Oral remibrutinib hits Phase 3 primary endpoint for inducible hives

March 5, 2026

Reduced gestational weight gain with lifestyle intervention

Cardiology

Replacing sedentary time with physical activity may lower risk of all-cause mortality

March 2, 2026

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Early initiation of rhythm-control for atrial fibrillation associated with lower risk of adverse cardiovascular outcomes

Delaying intrathecal therapy in leukemia may preclude need for cranial radiotherapy

Vemurafenib plus rituximab associated with complete response in refractory hairy-cell leukemia

Patient Basics: Middle-Ear Infection (Otitis Media)

Tympanostomy tubes not superior to medical management for recurrent acute otitis media

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports